NASDAQ:ABIO ARCA biopharma (ABIO) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range$28.80▼$599.0452-Week Range N/AVolume290,800 shsAverage Volume607,995 shsMarket Capitalization$34.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ARCA biopharma alerts: Email Address ARCA biopharma MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish37.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 2 Articles This WeekInsider TradingAcquiring Shares$1.67 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.15 out of 5 starsMedical Sector896th out of 910 stocksDiagnostic Substances Industry14th out of 14 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for ARCA biopharma.Read more about ARCA biopharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted37.10% of the float of ARCA biopharma has been sold short.Short Interest Ratio / Days to CoverARCA biopharma has a short interest ratio ("days to cover") of 50.3, which indicates bearish sentiment.Change versus previous monthShort interest in ARCA biopharma has recently increased by 13.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldARCA biopharma does not currently pay a dividend.Dividend GrowthARCA biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABIO. Previous Next 2.5 News and Social Media Coverage News SentimentARCA biopharma has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ARCA biopharma this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for ABIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added ARCA biopharma to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ARCA biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,666,176.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders30.90% of the stock of ARCA biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.44% of the stock of ARCA biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ARCA biopharma's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ARCA biopharma is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARCA biopharma is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ARCA biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About ARCA biopharma Stock (NASDAQ:ABIO)ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.Read More Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. ABIO Stock News HeadlinesAugust 21, 2024 | insidertrades.comHenderson Group Plc Janus Purchases 5,818 Shares of ARCA biopharma, Inc. (NASDAQ:ABIO) StockSeptember 5 at 3:01 AM | americanbankingnews.comARCA biopharma (NASDAQ:ABIO) Stock Rating Upgraded by StockNews.comSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …September 1, 2024 | americanbankingnews.comARCA biopharma (NASDAQ:ABIO) Shares Set to Reverse Split on Tuesday, September 3rdAugust 31, 2024 | americanbankingnews.comShort Interest in ARCA biopharma, Inc. (NASDAQ:ABIO) Increases By 13.4%August 30, 2024 | finanznachrichten.deARCA biopharma, Inc.: ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock SplitAugust 29, 2024 | globenewswire.comARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock SplitAugust 28, 2024 | americanbankingnews.comARCA biopharma, Inc. (NASDAQ:ABIO) to Issue $1.59 DividendSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 27, 2024 | finanznachrichten.deARCA biopharma, Inc.: ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka TherapeuticsAugust 26, 2024 | globenewswire.comARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka TherapeuticsAugust 24, 2024 | finanznachrichten.deARCA biopharma, Inc.: ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka TherapeuticsAugust 23, 2024 | globenewswire.comARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka TherapeuticsAugust 20, 2024 | msn.comWhat to know about the NASCAR trucks and ARCA weekend at the Milwaukee MileAugust 20, 2024 | msn.comWhy ARCA Biopharma Shares Are Trading Higher TodayAugust 17, 2024 | msn.comHow to watch Frankie Muniz’s NASCAR race at Michigan - ARCA Menards Series | Channel, stream, previewAugust 16, 2024 | globenewswire.comARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka TherapeuticsAugust 15, 2024 | msn.comFrankie Muniz announces first ARCA Menards Series starts since battling serious illnessSee More Headlines Receive ABIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Dividend Payable8/28/2024Ex-Dividend for 8/28 Dividend8/29/2024Today9/07/2024Next Earnings (Estimated)10/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABIO CUSIPN/A CIK907654 Webarcabio.com Phone(720) 940-2100Fax720-208-9261Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.18% Return on Assets-19.51% Debt Debt-to-Equity RatioN/A Current Ratio26.61 Quick Ratio26.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / BookN/AMiscellaneous Outstanding Shares14,507,000Free Float10,024,000Market Cap$34.82 million OptionableOptionable Beta0.91 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Thomas A. Keuer (Age 65)President, COO & Principal Executive Officer Comp: $400.8kMr. C. Jeffrey Dekker CPA (Age 59)CFO, Treasurer & Company Secretary Comp: $323.07kKey CompetitorsImmuCellNASDAQ:ICCCRani TherapeuticsNASDAQ:RANIAcumen PharmaceuticalsNASDAQ:ABOSSenti BiosciencesNASDAQ:SNTIAtyr PHARMANASDAQ:ATYRView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCBought 15,507,760 shares on 8/16/2024Ownership: 106.898%Driehaus Capital Management LLCBought 3,846,150 shares on 8/16/2024Ownership: 26.512%Henderson Group Plc JanusBought 40 shares on 8/16/2024Total: $16,876.80 ($421.92/share)Affinity Asset Advisors LLCBought 72,484 shares on 8/15/2024Ownership: 0.500%Cubist Systematic Strategies LLCBought 27,779 shares on 8/14/2024Ownership: 0.191%View All Insider TransactionsView All Institutional Transactions ABIO Stock Analysis - Frequently Asked Questions How were ARCA biopharma's earnings last quarter? ARCA biopharma, Inc. (NASDAQ:ABIO) posted its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($25.92) EPS for the quarter. When did ARCA biopharma's stock split? Shares of ARCA biopharma reverse split on Tuesday, September 3rd 2024. The 1-12 reverse split was announced on Friday, August 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Michael R. Bristow's approval rating as ARCA biopharma's CEO? 1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are ARCA biopharma's major shareholders? Top institutional shareholders of ARCA biopharma include Perceptive Advisors LLC (106.90%), Driehaus Capital Management LLC (26.51%), Cowen AND Company LLC (4.83%) and Renaissance Technologies LLC (0.50%). Insiders that own company stock include Fund Lp Funicular, Henderson Group Plc Janus and Christopher David Ozeroff. View institutional ownership trends. How do I buy shares of ARCA biopharma? Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ARCA biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO) and Gilead Sciences (GILD). This page (NASDAQ:ABIO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARCA biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARCA biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
